Sight Sciences announces publication of results on OMNI Surgical System

Sight Sciences (SGHT) announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System, OMNI. The study assessed OMNI, as well as its predecessors, Visco360 and Trab360, for the treatment of open-angle glaucoma. The paper reports both standalone and combined treatments to be effective in achieving long-term, clinically significant reductions in intraocular pressure and medication use, with sustained improvements over time. Key study findings: Treatment success was observed in approximately 89% of patients treated with either standalone or combined treatments after 6, 12, and 24 months. After 6 and 12 months, approximately 66-68% of patients treated with either standalone or combined treatments remained medication-free based on the results of the meta-analysis. OMNI significantly reduced IOP, with mean IOP below 18 mmHg at 12 months when used in combination with cataract surgery; this trend continued at 24 months. Meta-analysis confirmed comparable, statistically significant IOP reductions for standalone and combination therapy at 6, 12 and 24 months. Average IOP-lowering medication use decreased from a range of 0.9 to 3.4 medications at baseline to a range of 0.1 to 2.2 medications at month 12.